| BID | 4.82 | ASK | 5.86 | ||
| Open | 5.42 | Previous Close | 5.36 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 3.00 | Analyst Rating | Hold 3.00 | |
| Potential % | -43.82 | Finscreener Ranking | ★★ 45.69 | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★+ 42.82 | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★+ 40.87 | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | ★★★★ — - | |
| Price Range Ratio 52W % | 41.57 | Earnings Rating | Strong Buy | |
| Market Cap | 54.46M | Earnings Date | 9th Nov 2023 | |
| Alpha | 0.01 | Standard Deviation | 0.36 | |
| Beta | 2.80 |
Today's Price Range 4.905.61 | 52W Range 2.319.60 | 5 Year PE Ratio Range -8.20-9.80 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -0.37% | ||
| 1 Month | -11.00% | ||
| 3 Months | 63.30% | ||
| 6 Months | 1 343.24% | ||
| 1 Year | 1 340.09% | ||
| 3 Years | 78.00% | ||
| 5 Years | -89.16% | ||
| 10 Years | -83.48% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -140.93 | |||
ROE last 12 Months | -141.70 | |||
ROA (5Y Avg) | -27.83 | |||
ROA last 12 Months | -96.00 | |||
ROC (5Y Avg) | -141.71 | |||
ROC last 12 Months | -110.41 | |||
Return on invested Capital Q | -28.58 | |||
Return on invested Capital Y | -23.53 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 5.80 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.50 | ||||
| 4.46 | ||||
| 8.47 | ||||
| 18.60 | ||||
| -2.00 | ||||
| -0.29 | ||||
| 4.46 | ||||
| 0.09 | ||||
| 32.40M | ||||
| Forward PE | -5.36 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.00 | ||||
| 3.10 | ||||
| 0.20 | ||||
| 0.28 | ||||
| -1 945.90 | ||||
| Leverage Ratio | 1.70 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 52.00 | ||||
| -458.10 | ||||
| -454.80 | ||||
| -382.70 | ||||
| 5.93 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.03M | ||||
| 0.05 | ||||
| 23.85 | ||||
| 18.89 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | 36.00 |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.47 | -0.28 | 40.43 |
| Q01 2023 | -0.75 | -10.94 | -1 358.67 |
| Q04 2022 | -0.90 | -0.60 | 33.33 |
| Q03 2022 | -1.05 | -0.60 | 42.86 |
| Q02 2022 | - | -1.05 | - |
| Q01 2022 | -1.20 | -1.20 | 0.00 |
| Q04 2021 | -0.09 | -0.08 | 11.11 |
| Q03 2021 | -0.08 | -0.09 | -12.50 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.43 | 4.44 | Positive |
| 12/2023 QR | -0.37 | 15.91 | Positive |
| 12/2023 FY | -1.98 | 2.94 | Positive |
| 12/2024 FY | -1.00 | 17.36 | Positive |
| Next Report Date | 9th Nov 2023 |
| Estimated EPS Next Report | -0.43 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 69.96K |
| Shares Outstanding | 10.20K |
| Shares Float | 6.45M |
| Trades Count | 692 |
| Dollar Volume | 377.29K |
| Avg. Volume | 74.95K |
| Avg. Weekly Volume | 36.01K |
| Avg. Monthly Volume | 110.41K |
| Avg. Quarterly Volume | 78.41K |
Aspira Women's Health Inc. (NYSE: AWH) stock closed at 5.34 per share at the end of the most recent trading day (a -0.37% change compared to the prior day closing price) with a volume of 69.96K shares and market capitalization of 54.46M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 53 people. Aspira Women's Health Inc. CEO is Valerie Palmieri.
The one-year performance of Aspira Women's Health Inc. stock is 1340.09%, while year-to-date (YTD) performance is 1505.53%. AWH stock has a five-year performance of -89.16%. Its 52-week range is between 2.3087 and 9.6, which gives AWH stock a 52-week price range ratio of 41.57%
Aspira Women's Health Inc. currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 4.46, a price-to-sale (PS) ratio of 8.47, a price to cashflow ratio of 18.60, a PEG ratio of -, a ROA of -96.00%, a ROC of -110.41% and a ROE of -141.70%. The company’s profit margin is 5.93%, its EBITDA margin is -454.80%, and its revenue ttm is $6.03 Million , which makes it $0.05 revenue per share.
Of the last four earnings reports from Aspira Women's Health Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.43 for the next earnings report. Aspira Women's Health Inc.’s next earnings report date is 09th Nov 2023.
The consensus rating of Wall Street analysts for Aspira Women's Health Inc. is Hold (3), with a target price of $3, which is -43.82% compared to the current price. The earnings rating for Aspira Women's Health Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aspira Women's Health Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of 36.00%.
Aspira Women's Health Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.42, ATR14 : 0.58, CCI20 : 16.62, Chaikin Money Flow : -0.02, MACD : 0.37, Money Flow Index : 76.26, ROC : -11.88, RSI : 57.25, STOCH (14,3) : 40.19, STOCH RSI : 0.57, UO : 53.67, Williams %R : -59.81), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aspira Women's Health Inc. in the last 12-months were:
Aspira Women's Health Inc.
Aspira Womens Health Inc is transforming women's health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 plus combines its FDA-cleared products OVA1 and OVERA to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiX testing offers both targeted and a more comprehensive genetic testing options with a gynecologic focus. Its focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment.
CEO: Valerie Palmieri
Telephone: +1 512 519-0400
Address: 12117 Bee Caves Road, Building Three, Austin 78738, TX, US
Number of employees: 53
TipRanks News for AWH
Mon, 11 Sep 2023 12:32 GMT Aspira Womens Health appoints Berry as new Chief Scientific Officer
- TipRanks. All rights reserved.
